START: Acute Asthma Exacerbation
Patient presents with acute bronchospasm/wheezing
All Pathways
Emergency MedicineEmergency
Acute Asthma Exacerbation (GINA 2025)
Acute Asthma Exacerbation (GINA 2025): START: Acute Asthma Exacerbation → Initial Assessment → Severity Classification? → LIFE-THREATENING → ICU/Resusci...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Initial Assessment
Rapid evaluation while initiating treatment
- ABC assessment
- Brief history: onset, triggers, medications
- PEF or FEV1 if possible (not mandatory)
- SpO2, HR, RR, accessory muscle use
- Ability to speak (sentences vs words)
- Alert level
03Decision Severity Classification?
Classify severity to guide treatment intensity
- MILD-MODERATE: Talks in phrases, prefers sitting, not agitated, RR increased, no accessory muscles, HR 100-120, SpO2 90-95%, PEF >50%
- SEVERE: Talks in words, sits hunched, agitated, RR >30, accessory muscles, HR >120, SpO2 <90%, PEF ≤50%
- LIFE-THREATENING: Drowsy/confused, silent chest, bradycardia, SpO2 <90%, unable to perform PEF
04Warning LIFE-THREATENING
Immediate resuscitation + ICU
- Drowsy, confused, or silent chest
- Bradycardia or cyanosis
- Poor respiratory effort
- PEF not obtainable
05Action ICU/Resuscitation
Aggressive intervention
- High-flow O2 to maintain SpO2 93-95%
- Continuous nebulized SABA + ipratropium
- IV corticosteroids immediately
- IV magnesium sulfate 2g over 20 min
- Consider IV salbutamol or terbutaline
- Prepare for intubation (ketamine preferred)
- Call ICU/anesthesia early
06Warning ICU Admission
Critical care required
- Impending respiratory failure
- Altered consciousness
- Requiring non-invasive or invasive ventilation
- Hemodynamic instability
07Action SEVERE Exacerbation
Aggressive treatment in ED
- O2 to maintain SpO2 93-95%
- SABA: 4-10 puffs q20min x 3 via spacer OR nebulized 2.5-5mg q20min
- Ipratropium 500 mcg nebulized q20min x 3
- Prednisolone 40-50 mg PO OR IV hydrocortisone 200 mg
- Consider IV magnesium 2g over 20 min if poor response
08Decision Reassess at 1 Hour
Evaluate response to initial treatment
- GOOD RESPONSE: PEF 60-80%, symptoms improved, SpO2 >94%
- INCOMPLETE RESPONSE: PEF 40-60%, persistent symptoms
- POOR RESPONSE: PEF <40%, worsening or no improvement
09Action Good Response
Prepare for discharge
- Continue SABA q1-4hr as needed
- Oral steroids: Prednisolone 40-50 mg daily x 5-7 days
- Review inhaler technique
- Assess for ICS/LABA controller need
- Written action plan
10Outcome Discharge with Action Plan
Safe for outpatient management
- PEF >70% predicted
- SpO2 >94% on room air
- Adequate symptom relief
- Adequate inhaler technique
- Follow-up arranged within 2-7 days
11Action Incomplete Response
Intensify treatment
- Continue SABA q1hr
- Add ipratropium if not given
- Consider IV magnesium 2g over 20 min
- Reassess in 1-2 hours
- Consider admission
12Outcome Admit to Hospital
Requires inpatient care
- Ongoing O2 requirement
- PEF <60% after treatment
- High risk features (previous ICU, intubation)
- Comorbidities
- Inadequate home support
13Action Poor Response
Escalate care
- Move to severe/life-threatening pathway
- IV magnesium if not given
- Consider IV beta-agonist
- ICU consultation
- Prepare for ventilation if deteriorating
- Path rejoins step 12Shared downstream outcome
- Path rejoins step 06Shared downstream outcome
14Action MILD-MODERATE Exacerbation
Standard treatment
- SABA: 4-10 puffs via spacer q20min x 1hr OR nebulized 2.5mg q20min
- O2 if SpO2 <93% (target 93-95%)
- Prednisolone 40-50 mg PO
- Consider ipratropium if severe symptoms or poor response
- Path rejoins step 08Shared downstream outcome
Guideline Source
Global Initiative for Asthma (GINA) 2025 Report
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address chronic asthma management
- Simplified severity assessment - use clinical judgment
- Drug dosing may vary by institution
- Does not replace pulmonology consultation for refractory cases
- Pediatric dosing requires weight-based adjustments
Contraindicated Populations
neonates
Applicable Regions
EUUSGlobal
US: Consider NAEPP guidelines as supplement
Global: GINA is international standard; local protocols may vary
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Acute Asthma Exacerbation (GINA 2025)?
The Acute Asthma Exacerbation (GINA 2025) is a emergency clinical algorithm for Emergency Medicine. It provides a structured decision tree to guide clinical decision-making, based on Global Initiative for Asthma (GINA) 2025 Report.
What guideline is the Acute Asthma Exacerbation (GINA 2025) based on?
This algorithm is based on Global Initiative for Asthma (GINA) 2025 Report (DOI: ginasthma.org).
What are the limitations of the Acute Asthma Exacerbation (GINA 2025)?
Known limitations include: Does not address chronic asthma management; Simplified severity assessment - use clinical judgment; Drug dosing may vary by institution; Does not replace pulmonology consultation for refractory cases; Pediatric dosing requires weight-based adjustments. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Acute Asthma Exacerbation (GINA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free